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Abstract
The aim. Based on the analysis and comprehensive clinical and neurological evaluation of the results to substantiate the 
effectiveness of transcranial magnetic stimulation (TMS) in the treatment and rehabilitation of patients with multiple sclerosis (MS). 
Methods. A total of 110 MS patients were included in the study. The control group consisted of 30 patients who received 
pathogenetic therapy and 80 patients who underwent a course of rhythmic transcranial magnetic stimulation (rTMS) together with 
pathogenetic therapy. 
Results. The results obtained during the study indicate the complex multifactorial nature of fatigue and its significant impact 
on the clinical manifestations of MS. Also, the use of rTMS reduced the severity of the main neurological symptoms of MS. The 
improvement in the overall EDSS scale in the group of patients receiving rTMS was statistically significant: from 5.0 ± 1.9 points to 
4.5 ± 2.0 points (p < 0.01), in the comparison group (p > 0.05). Under the influence of TMS, gait function improved, but these indi-
cators were statistically insignificant (p > 0.05). The greatest effect of rTMS was obtained on the manifestations of fatigue and also 
extended to its cognitive and psychosocial components. The obtained patterns are confirmed in the analysis of indicators on the SCA 
and FS scales. Involvement in the treatment of patients with MS rTMS allowed to achieve a significant reduction in the manifesta-
tions of all components of fatigue: from 76.0 ± 20.9 points to 75.5 ± 20.5 points (p < 0.05).
The data obtained during the study confirm the effectiveness, safety and viability of non-invasive neuromodulation by rTMS 
in the treatment and rehabilitation of patients with MS.
Conclusions. The use of rTMS has a positive effect on the manifestations of fatigue, both motor and cognitive, in patients 
with MS at all types of course and at different stages of progression. Non-invasiveness, safety and ease of use, the possibility of 
differentiated use allow the use of rTMS in the clinic of rehabilitation treatment and become an important component of active drug 
and non-drug rehabilitation of patients with MS.
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1. Introduction
Multiple sclerosis is a complex, heterogeneous disease associated with increasing disability. 
According to the WHO, among neurological diseases, multiple sclerosis is one of the main causes 
of persistent disability of young people [1].
Despite the presence of advanced treatments that modify the disease, as well as symp-
tomatic treatments that can reduce the activity and progression of the disease, there is a need for 
comprehensive rehabilitation measures to improve quality of life [2, 3]. In recent years, in addi-
tion to improving the existing arsenal of neurorehabilitation methods (exercise therapy, kinesio-
therapy, physiotherapy), there are new techniques that can improve the patient’s recovery [4, 5]. 
Recent methods include non-invasive neuromodulation methods, such as rhythmic transcranial 
magnetic stimulation (rTMS) [6, 7]. A feature of the rTMS method is its non-invasiveness, safety 
and ease of use [8, 9]. All these qualities and the possibility of differentiated use allow the use 
of rTMS in the clinic of rehabilitation treatment and become an important component of active 
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drug and non-drug rehabilitation of patients [10, 11]. In this regard, the TMS method can act as 
a tool for local individual modulator of certain areas of the cortex (activation or inhibition) in 
the mode required for a particular patient and have a positive effect on certain symptoms and 
syndromes [12, 13].
MS has a wide range of clinical manifestations [14, 15]. Fatigue is one of the leading syn-
dromes observed in this category of patients and which has two components in its structure – motor 
and non-motor [16, 17]. All objective methods are aimed at quantifying each of them [18].
The aim of the research. Based on the analysis and comprehensive clinical and neurologi-
cal evaluation of the results to substantiate the effectiveness of TMS in the treatment and rehabili-
tation of patients with MS.
2. Materials and methods
The study was conducted from 2019 to 2021 in the Department of Autoimmune and Dege-
nerative Diseases of the Nervous System on the basis of the State Institution «Institute of Neuro-
logy, Psychiatry and Narcology of NAMS of Ukraine». The study involved 110 patients diagnosed 
with MS. The diagnosis was made according to the criteria of McDonald et al., 2017.
All procedures in this study are in line with the ethical standards of the 1975 Helsinki Decla-
ration, as revised in 2008, and national legislation. Informed consent to participate in the study was 
discussed and signed by all study participants. Meeting of the Commission on Ethics and Deonto-
logy (minutes No. 7B of July 19, 2019) of the «Institute of Neurology, Psychiatry and Narcology 
of NAMS of Ukraine».
All patients received disease-modifying therapy drugs – drugs of the 1st (interferon beta 
1-β, interferon beta 1-α, glatiramer acetate, teriflunomide) or 2nd line (mitoxantrone, ocrelizumab, 
alemtuzumab, cladribine) in combination with pulse therapy with methylprednisolone in case of 
exacerbation of the disease.
The study was performed in two stages. The first stage included the study of clinical and 
neurological features depending on the type of course, taking into account the motor and cognitive 
components of fatigue in patients with MS. The second stage was devoted to assessing the impact 
of rTMS on the components of fatigue.
According to the aim of the study, all patients were randomly divided into two groups: 
I – 80 (72.7 %) patients who underwent TMS, and II (comparison group) – 30 (27.3 %) patients who 
received only pathogenetic therapy.
The neurological status of patients was studied according to generally accepted criteria and 
included mental status, condition of cranial nerves, motor system, muscular strength, gait, statics 
and coordination of movements, sensitivity, state of reflex system, autonomic nervous system.
Clinical and neurological examination of patients with MS was performed using the FS 
and EDSS scales (Definitions for a standardized, quantified neurological examination and as-
sessment of Kurtzke’s Functional Systems and Expanded. Disability Status Scale in Multiple 
Sclerosis, 1983). The severity of the effect of fatigue was assessed by the scales MFIS (Modified 
Fatigue Scale Impad, 1998), FSS (Krupp et al., 1989), SCA. 
RTMS was used for non-invasive neuromodulation during treatment and rehabilitation. 
The course of treatment was performed on a MagVenture, MagPro X100 and an 8-shaped induc-
tor (coil). All patients were tested using a safety questionnaire and selected according to the indi-
cations and contraindications of rTMS [9]. Depending on the leading clinical manifestations, dif-
ferent protocols for rTMS were used. Protocols with high-frequency stimulation of DLPFC zones 
and primary motor cortex, M1 zone (D, S) with frequency 10 Hz, amplitude 90–100 % of WWII, 
duration of 10 sessions, from 1600 to 2000 stimuli per session were selected [19].
Statistical analysis of the data was performed using the licensed application package 
Statistica 13. Assessment of the nature of the distribution of quantitative characteristics was per-
formed using the Shapiro-Wilk test. Intergroup analysis of differences was performed using the 
nonparametric Mann-Whitney test for quantitative traits and using Fisher’s exact test for catego-
rized traits. Correlation analysis was performed using Spearman’s rank correlation method. The 
level of statistical significance of differences and correlations p < 0.05 was considered acceptable.
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Among patients with MS, women dominated: 66.4 % vs. 33.6 % of men; the largest 
proportion of women was found in the remitting type – 74.6 %, the smallest – in the initially 
progressive (50.0 %), however, gender differences between different types of MS are not statistical-
ly significant (p > 0.05) (Table 1). 
Table 1
Gender structure of the studied contingent
Sex
Primarily progressive Secondarily progressive Remitting Total
abs. M ± m abs. M ± m abs. M ± m abs. M ± m
Men 7 50.0 ± 13.4 15 40.5 ± 8.1 15 25.4 ± 5.7 37 33.6 ± 4.5
Women 7 50.0 ± 13.4 22 59.5 ± 8.1 44 74.6 ± 5.7 73 66.4 ± 4.5
Total 14 100.0 37 100.0 59 100.0 110 100.0
The mean age of the examined patients at the time of the study was 39.7 ± 9.2 years; the 
oldest were patients with primary progressive type of course (42.7 ± 7.4 years), slightly younger – with 
secondary progressive (40.1 ± 11.1 years), and the youngest – with remitting type (38.7 ± 8.3 years), 
although the differences between the groups are statistically insignificant (p > 0.05).
The average duration of MS in the examined patients was 6.7 ± 4.2 years; the largest – in pa-
tients with primary progressive type (11.1 ± 4.7 years), insignificant (p > 0.05) smaller – in patients 
with secondary progressive type (8.8 ± 3.8 years), and significant p < 0.05) less – in patients with 
remitting type (4.4 ± 2.7 points). 
In 54.5 % the process was active at the time of the survey, in 45.5 % – inactive. The largest 
proportion of patients with active process was in the secondary-progressive type (70.3 %), and the 
smallest – in the primary-progressive (21.4 %)
The nature of MS in most subjects was monosyndromic (73.6 %); the proportion of polysyn-
dromic variants differed slightly in different types and was the largest in the primary progressive 
variant (35.7 %), and the smallest – in the secondary – progressive (21.6 %) (Fig. 1).
Fig. 1. The nature of MS in the examined patients
Analysis of lateralization revealed a predominance of left-sided lesions (43.6 %), some-
what less often found right-handed (30.9 %) and rarely symmetrical (25.5 %). Left-sided lesions 
dominated in patients with secondary-progressive type (67.6 %), and right-sided and symmetrical – 






































Fig. 2. Features of lateralization of the process in the examined patients
The peculiarities of fatigue manifestations in MS were studied in detail. Our data allow us 
to consider fatigue in MS as a separate clinical and socio-medical phenomenon, characterized by 
certain clinical and phenomenological features, characteristics of functioning and quality of life of 
patients, as well as the mutual influence of various clinical factors.
When analyzing the severity of fatigue in MS according to the MFIS scale, fairly high va-
lues were found for all subscales (Fig. 3). Thus, the index on the physical subscale in all patients 
was 16.5 ± 11.2 points, on the cognitive subscale – 23.8 ± 10.1 points, on the psychosocial subscale – 
4.0 ± 2.1 points. The overall MFIS score in the examined patients was 44.3 ± 23.0 points. At the 
same time, there is a clear tendency to significantly more pronounced fatigue in patients with 
primary progressive type of MS, less – in patients with secondary progressive type, and the least – 
in patients with remitting type.
Fig. 3. Correlations between fatigue rates and the overall severity  
of MS symptoms on the EDSS scale
Similarly, the indicators on the FS and ASS scales reflected the same trends (Fig. 3). Thus, 
the overall score on the FSS scale in all patients was 40.7 ± 13.7 points, in patients with prima-
ry progressive type – 52.6 ± 9.9 points, with secondary progressive type – 49.8 ± 8.7 points, with 
remitting type – 32.1 ± 11.1 points. The indicator on the ASS scale in all examined patients was 
76.1 ± 20.9 points, in patients with primary progressive type – 96.9 ± 13.4 points, with secondary 
progressive type – 89.4 ± 13.1 points, and when remitting type – 62.9 ± 16.7 points.
At the same time, the clinical and pathogenetic mechanisms of fatigue in MS are com-
plex and multifactorial [20]. This was confirmed by the results of non-parametric correlation 
analysis. Thus, none of the indicators of the severity of clinical symptoms of MS on the FS 
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impaired sensitivity, pelvic dysfunction and intelligence) did not show significant correlations with 
fatigue (p > 0.05). In this case, the overall severity of the EDSS scale was associated with a direct 
correlation with the severity of fatigue according to all scales used in our study (Fig. 3).
As the general indicator on the EDSS scale is defined mainly by indications of loss of gait 
function, especially at heavy forms of a disease, the inverse correlations between preservation of 
gait function (distance which the patient can pass) and indicators of expressiveness of fatigue are 
natural (Fig. 4).
Fig. 4. Correlations between gait function and fatigue rates
In addition, significant correlations were found between the duration of the disease and the 
severity of fatigue, but primarily due to the cognitive component (Fig. 5). The correlations between 
age and fatigue rates were not statistically significant (p > 0.05), indicating a lack of relationship 
between these factors.
Fig. 5. Correlations between fatigue and disease duration
It should be noted that the correlations are mostly weak (except for ASS), which indicates 
a complex multifactorial nature of fatigue in MS and the inability to explain it only by the formal 
characteristics of the severity of neurological symptoms.
The introduction of TMS in the complex of treatment and rehabilitation measures 
for MS has improved the overall condition of patients and achieved significant changes in some 
important areas.
The use of TMS allowed to some extent reduce the severity of the main neurological symp-
toms of MS, although the dynamics here was ambiguous and not very pronounced (Table 2).
Neither traditional nor the proposed therapy did not affect the optic nerve damage: the 
indicators did not change under the influence of treatment. Symptoms of cranial nerve dis-
orders in the comparison group during therapy slightly worsened: from 1.9 ± 1.1 points to 
2.0 ± 1.0 points (p > 0.05), and in the group receiving TMS, slightly decreased: from 1.5 ± 1.0 points 
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to 1.4 ± 1.0 points (p > 0.05). Symptoms of pyramidal pathway damage in the comparison group de-
creased slightly: from 4.1 ± 1.1 points to 3.5 ± 1.3 points (p > 0.05), while in the intervention group 
the improvement was significant: from 3.6 ± 1.4 points to 3.3 ± 1.3 points (p < 0.01). Traditional 
therapy was significantly effective against coordination disorders, where the FS scale decreased 
from 3.8 ± 1.2 points to 3.3 ± 1.2 points (p < 0.05), a similar effect was achieved in the intervention 
group, where the indicator decreased from 3.1 ± 1.4 points to 2.8 ± 1.3 points (p < 0.05). Dynamics 
in the symptoms of pelvic disorders under the influence of traditional and proposed therapy was 
absent. In the group of traditional therapy there were no changes in the intellectual component of 
the FS scale, while in patients receiving TMS, there was some improvement: from 1.5 ± 0.8 points 
to 1.4 ± 0.8 points, although these changes were statistically insignificant (p > 0.05).
Table 2
Indicators on FS and EDSS scales before and after TMS, M ± m, (in points)
Indicator
Comparison group, n = 30 Intervention group, n = 80
before treatment after treatment before treatment after treatment
Optic nerve damage 1.5 ± 0.9 1.5 ± 0.9 1.5 ± 0.9 1.5 ± 0.9
Disorders of the cranial nerves 1.9 ± 1.1 2.0 ± 1.0 1.5 ± 1.0 1.4 ± 1.0
Symptoms of pyramidal pathway damage 4.1 ± 1.1 3.5 ± 1.3 3.6 ± 1.4 3.3 ± 1.3**
Impaired coordination 3.8 ± 1.2 3.3 ± 1.2 3.1 ± 1.4 2.8 ± 1.3*
Sensitivity disorders 1.4 ± 1.2 1.4 ± 1.2 1.1 ± 1.1 1.0 ± 1.0*
Pelvic dysfunction 1.6 ± 0.9 1.6 ± 1.1 1.2 ± 1.0 1.2 ± 1.0
Disorders of intelligence 1.9 ± 0.8 1.9 ± 0.8 1.5 ± 0.8 1.4 ± 0.8
Indicator on the EDSS scale 5.5 ± 1.5 5.1 ± 1.9 5.0 ± 1.9 4.5 ± 2.0**
Note: * – discrepancies are statistically significant (p < 0.05); ** – differences are statistically significant (p < 0.01)
The overall EDSS score in the comparison group improved during treatment: from 
5.5 ± 1.5 points to 5.1 ± 1.9 points, but this improvement was statistically insignificant (p > 0.05). 
In the group of patients receiving TMS, the improvement was statistically significant: from 
5.0 ± 1.9 points to 4.5 ± 2.0 points (p < 0.01).
Certain positive changes under the influence of therapy have occurred in relation to the 
restoration of gait function (Table 3).
Thus, under the influence of traditional and proposed therapy, gait performance improved 
somewhat: the number of patients who were able to restore gait without restrictions increased and 
the number of patients with gait restrictions decreased. In the intervention group, a slightly greater 
improvement in gait recovery was achieved than in the comparison group, however, these dif-
ferences were statistically insignificant (p > 0.05).
Important was the therapeutic effect of TMS on the manifestations of fatigue in MS. Given 
the complex nature of asthenic manifestations in MS, we studied the dynamics of the various com-
ponents of fatigue using several valid and reliable techniques.
Analysis of the dynamics of indicators on the MFIS scale allowed to establish the pres-
ence of a certain positive dynamics of fatigue under the influence of traditional therapy. Thus, the 
indicator on the physical subscale decreased from 16.2 ± 11.2 points to 15.9 ± 11.1 points, on the 
cognitive subscale from 22.7 ± 11.1 points to 22.3 ± 10.9 points, on the psychosocial subscale from 
4.0 ± 2.1 points to 3.9 ± 2.1 points (Table 4). 
The overall score on the MFIS scale during treatment according to the traditional scheme 
decreased from 43.0 ± 23.9 points to 42.0 ± 23.4 points. At the same time, the decrease in indicators 
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on all subscales, as well as the integrated fatigue rate on the MFIS scale under the influence of 
traditional therapy was statistically insignificant (p > 0.05).
Table 3
The results of the study of gait function before and after TMS
Gait
Comparison group, n = 30 Intervention group, n = 80
before treatment after treatment before treatment after treatment
abs. M ± m abs. M ± m abs. M ± m abs. M ± m
Without limits 6 20.0 ± 7.3 8 26.7 ± 8.1 27 33.6 ± 5.3 30 37.2 ± 5.4
more than 500 m 1 3.3 ± 3.3 1 3.3 ± 3.3 5 6.3 ± 2.7 9 11.3 ± 3.5
300–500 m 3 10.0 ± 5.5 1 3.3 ± 3.3 7 8.8 ± 3.2 3 3.8 ± 2.1
200–300 m 2 6.7 ± 4.6 3 10.0 ± 5.5 6 7.5 ± 2.9 5 6.3 ± 2.7
100–200 m 9 30.0 ± 8.4 9 30.0 ± 8.4 12 15.0 ± 4.0 13 16.3 ± 4.1
20–100 m 5 16.7 ± 6.8 5 16.7 ± 6.8 13 16.3 ± 4.1 13 16.3 ± 4.1
A few steps 3 10.0 ± 5.5 2 6.7 ± 4.6 8 10.0 ± 3.4 5 6.3 ± 2.7
None 1 3.3 ± 3.3 1 3.3 ± 3.3 2 2.5 ± 1.7 2 2.5 ± 1.7
Total 30 100 30 100 80 100 80 100
Table 4
Indicators on the MFIS scale before and after treatment, M ± m (in points)
Indicator
Comparison group, n = 30 Intervention group, n = 80
before treatment after treatment before treatment after treatment
Physical subscale 16.2 ± 11.2 15.9 ± 11.1 16.6 ± 11.3 16.3 ± 11.3*
Cognitive subscale 22.7 ± 11.1 22.3 ± 10.9 24.3 ± 9.8 24.0 ± 9.8*
Psychosocial subscale 4.0 ± 2.1 3.9 ± 2.1’ 4.0 ± 2.1 3.8 ± 2.1*
Overall indicator for MFIS 43.0 ± 23.9 42.0 ± 23.4 44.8 ± 22.7 44.1 ± 22.7*
Note: * – discrepancies are statistically significant (p < 0.05)
Instead, in the process of treatment with TMS it was possible to achieve a significant 
improvement in fatigue, and the therapeutic effect of TMS also extended to its cognitive and 
psychosocial components. Thus, the indicator on the physical scale under the influence of treatment 
according to the proposed scheme decreased from 16.6 ± 11.3 points to 16.3 ± 11.3 points (p < 0.05), 
on the cognitive subscale – from 24.3 ± 9, 8 points to 24.0 ± 9.8 points (p < 0.05), on the psychoso-
cial subscale – from 4.0 ± 2.1 points to 3.8 ± 2.1 points (p < 0.05). The overall indicator on the MFIS 
scale under the influence of the proposed scheme decreased significantly: from 44.8 ± 22.7 points 
to 44.1 ± 22.7 points (p < 0.05).
At the same time, it should be noted that the dynamics of fatigue during treatment was 
uneven and differed in different groups depending on the type of MS. Thus, in patients with pri-
mary progressive and secondary progressive types of MS, similar levels of fatigue were observed; 
the severity of asthenic manifestations in them was related to the duration of the disease and was 
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determined mainly by physical components. In contrast, in the remitting type of MS, the overall 
low rate of fatigue was due to the presence in this group of a significant number of patients with 
mild course and low severity of pathological manifestations, including in the cognitive and psy-
chosocial spheres. At the same time, patients with very high cognitive and psychosocial fatigue 
subscales were found in this group; indicators in these patients exceeded those found in patients 
with primary progressive and secondary progressive types. The positive dynamics of asthenia in 
the group of patients with remitting type was largely due to the reduction of asthenic manifestations 
associated with cognitive and psychosocial dysfunction.
The obtained patterns are confirmed in the analysis of indicators on the ASS and FSS scales 
during treatment (Table 5).
Table 5
Indicators on the ASS and FSS scales before and after treatment, M ± m (in points)
Indicator
Comparison group, n = 30 Intervention group, n = 80
before treatment after treatment before treatment after treatment
Indicator for ASS 76.6 ± 21.1 75.8 ± 20.5 76.0 ± 20.9 75.5 ± 20.5*
Overall FSS score 41.3 ± 14.0 40.9 ± 13.7 40.4 ± 13.7 40.2 ± 13.6*
Note: * – discrepancies are statistically significant (p < 0.05)
Thus, in the process of treatment according to the traditional scheme, the fatigue rate on 
the SCA scale decreased from 76.6 ± 21.1 points to 75.8 ± 20.5 points, however, this decrease was 
statistically insignificant (p > 0.05). Instead, the proposed scheme allowed to achieve a significant 
reduction in fatigue: from 76.0 ± 20.9 points to 75.5 ± 20.5 points (p < 0.05).
Similarly, the FSS scale in the comparison group decreased slightly: from 41.3 ± 14.0 points 
to 40.9 ± 13.7 points (p > 0.05), and in the intervention group significantly: from 40.4 ± 13.7 points 
to 40.2 ± 13.6 points.
Thus, the proposed scheme of intervention using TMS has significantly reduced the man-
ifestations of asthenia in patients with MS, including through the impact on the cognitive and 
psychosocial components of fatigue.
Adverse events were observed in 68.75 % of patients during rTMS. They depended on the 
chosen protocol. In most cases (72.7 %) patients complained of discomfort at the site of stimulation, 
moderate local pain. Tics of facial muscles were observed in 5 % of cases. Also, 23.63 % of patients 
complained of dizziness, drowsiness and fatigue after the session. All of the above side effects were 
temporary and passed after the end of the rTMS session after some time.
4. Discussion
MS refers to diseases that steadily progress and lead to early disability. Early administration 
of disease-modifying therapy (DMT) drugs can inhibit the demyelinating process, but not cure [2, 3]. 
This disease mainly affects people of young, working age. 
Therefore, rehabilitation at the very initial stages of MS development, along with taking 
DMT drugs, is a priority [4]. Recently, much attention has been paid by researchers to the study of 
various methods of non-invasive neuromodulation. The issue of differentiated application of these 
methods in the treatment of MS is debatable [19].
The non-invasive method of neuromodulation includes rTMS. Safety, non-invasiveness and 
a wide range of effects on MS symptoms have allowed us to suggest a possible positive effect 
of rTMS on the components of fatigue.
Fatigue makes a significant contribution to disability and significantly reduces the quality 
of life [16]. The peculiarities of fatigue manifestations in MS were studied in the work. Modern 
valid scales FSS, MFIS, asthenic state scale (ASS) were used. The data obtained during the study 
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allowed us to consider fatigue in MS as a separate clinical and socio-medical phenomenon, charac-
terized by certain clinical and phenomenological features and the mutual influence of different 
clinical factors. 
Thus, in the works of Vinychuk S. M. no direct correlations were obtained with the degree 
of disability [21]. However, according to our study, the overall severity of the EDSS scale was found 
to be directly correlated with the severity of fatigue on all scales used in the study. And the inverse 
correlation was obtained between the preservation of gait function (distance that the patient can 
walk) and indicators of the severity of fatigue.
However, none of the indicators of the severity of clinical symptoms of MS on the FS scale 
showed significant correlations with fatigue (p > 0.05). Indicators of fatigue correlate with the du-
ration of the disease, but have no relationship with age (p > 0.05). Such tendencies coincide with the 
published results of Kopchak O. O. [18].
The results obtained during the study indicate the complex multifactorial nature of fa-
tigue and its significant impact on the clinical manifestations of MS. The second stage was to 
study the effect of TMS on the leading symptoms of MS, primarily on the components of fa-
tigue. Protocols with high-frequency stimulation of DLPFC and primary motor cortex zones, 
M1 (D, S) zones with a frequency of 10 Hz, amplitude of 90–100 %, duration of 10 sessions, 
from 1600 to 2000 stimuli per session were selected. The use of TMS reduced the severity of 
the main neurological symptoms of MS. This was confirmed in the works of Iodice R., 2017, 
Leocani L., 2019 [6, 13]. The improvement in the overall EDSS score in the group of patients 
receiving TMS was statistically significant: from 5.0 ± 1.9 points to 4.5 ± 2.0 points (p < 0.01), 
in the comparison group (p > 0.05). Under the influence of TMS, gait function improved, but 
these indicators were statistically insignificant (p > 0.05). The greatest effect of rTMS was ob-
tained on the manifestations of fatigue and also extended to its cognitive and psychosocial com-
ponents. The dynamics of fatigue indicators under the influence of rTMS was uneven and de-
pended on the type of MS. Improvement from non-invasive neuromodulation was observed in 
all types of MS. The obtained patterns are confirmed in the analysis of indicators on the ASS 
and FS scales. Involvement in the treatment of patients with MS rTMS allowed to achieve a sig-
nificant reduction in the manifestations of all components of fatigue: from 76.0 ± 20.9 points to 
75.5 ± 20.5 points (p < 0.05).
The data obtained during the study confirm the effectiveness, safety and viability of non-in-
vasive neuromodulation by rTMS in the treatment and rehabilitation of patients with MS.
Study limitations. This study combines the observation of MS patients during one course 
of rTMS (10 sessions, two weeks) on the background of the use of drug-modifying therapy.
Prospects for further research. Since the results obtained during the study indicate a pos-
itive effect of rTMS on the clinical manifestations of MS, primarily on the components of fatigue, 
we plan in the following studies to develop an algorithm for non-invasive neuromodulation in the 
treatment of MS depending on MS activity.
5. Conclusions
Fatigue is a very common (78 %) symptom in the structure of neurological disorders in pa-
tients with MS, which deepens disability and affects quality of life.
The symptom of fatigue in patients with MS, which contains both motor and cognitive com-
ponents, differently affect the neurological manifestations at different types of course, at different 
stages of progression.
The level of motor fatigue correlates with the level of disability. There is a connection be-
tween the level of motor fatigue and the level of damage to the pyramidal pathways. Cognitive 
fatigue is not connected with age, sex (p > 0.05), but moderately correlates with level of disability 
and considerably correlates with duration of a disease (p < 0.05).
The use of rTMS has a positive effect on the manifestations of fatigue, both motor and cogni-
tive, in patients with MS at all types of course and at different stages of progression (76.0 ± 20.9 points 
to 75.5 ± 20.5 points, at p < 0.05), primarily due to the cognitive component (16.6 ± 11.3 points to 
16.3 ± 11.3 points, at p < 0.05), to a lesser extent due to the motor component.
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Non-invasiveness, safety and ease of use, the possibility of differentiated use allow the use 
of TMS in the clinic of rehabilitation and become an important component of active drug and non-
drug rehabilitation of patients.
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